hapabapa BioVie ( NASDAQ: BIVI ) added ~15% in early premarket trading on Thursday after the company said that the U.S. FDA aligned with its plans for its mid-stage SUNRISE-PD trial targeted at its Parkinson’s disease candidate, bezisterim.
Following FDA feedback on the trial design, BioVie ( BIVI ) noted that the SUNRISE-PD had already included a secondary endpoint, incorporating a clinical measure the FDA had recommended as a primary endpoint. Therefore, “BioVie believes it can proceed with the SUNRISE-PD trial as planned without protocol amendments,” the company added. As a result, the company said it is currently working on trial start-up activities to begin patient screening in Q4 2024.
The 60-subject Phase 2 trial is designed to evaluate bezisterim’s impact on Parkinson’s disease symptoms over 20 weeks, from the initial screening to the safety follow-up. SUNRISE-PD, a placebo-controlled trial, is expected to target newly diagnosed patients with Parkinson’s disease. More on BioVie Inc.
Seeking Alpha’s Quant Rating on BioVie Inc. Historical earnings data for BioVie Inc. Financial information for BioVie Inc.
.
